re: skint xcel, page-9

re: skint xcel Latest activities and cashflow report has +$1M in the bank and $5M in the standby equity facility. That should be plenty to get through phase II trials without further capital raisings. Shame the $5M will release another 100M shares at current 5c SP.

With the great phase I trial results and Orphan Drug Status they do have all the pieces of the puzzle coming together, albeit it slowly. Solbec is still extremely high risk but the rewards are there for the brave (and patient) if phase II trial results are as good as they hope.

A lazy 100k at 5c would be good for the bottom drawer if they could get Coramsine through phase II trials and partnered out in two-three years.